PHKA1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon14.
Images
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon14.
Alternative names
5330411D17, 9830108K24Rik, KPB1_HUMAN, MGC132604, PHKA, Pcyt1b, Phosphorylase b kinase regulatory subunit alpha, Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform, Phosphorylase kinase alpha M subunit, RP23 210E20.1, kinase PHKA1, phosphorylase kinase, alpha 1 (muscle), skeletal muscle isoform
What's included?
Recommended products
PHKA1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon14.
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon14.
- Concentration
Properties
- Gene name
- PHKA1
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing, Western blot
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
PHKA1 also known as phosphorylase kinase alpha 1 is a regulatory subunit of the phosphorylase kinase enzyme complex with a molecular mass around 138 kDa. This protein is mainly expressed in skeletal muscle and heart tissue. PHKA1 plays an important role in glycogen metabolism by regulating the conversion of phosphorylase b to phosphorylase a which ultimately leads to glycogen breakdown.
- Biological function summary
Glycogen metabolism involves PHKA1 as part of the phosphorylase kinase complex. This complex exists in the muscle and liver and includes alpha beta gamma and delta subunits. PHKA1 binds together with these subunits to form a large complex helping to regulate the activity state of the enzyme. The regulation of glycogen phosphorylase is important for maintaining energy supply in cells particularly during physical activity.
- Pathways
The activity of PHKA1 impacts glycogenolysis which is a significant metabolic pathway responsible for breaking down glycogen into glucose-1-phosphate. This pathway involves other proteins like glycogen phosphorylase and phosphoprotein phosphatase 1. PHKA1 has interactions within the cascade that ensures proper glycogen breakdown especially during conditions requiring increased energy output.
- Associated diseases and disorders
Mutations in PHKA1 are linked to glycogen storage disease type IXd (GSD IXd) which primarily affects muscle tissue. This condition features exercise intolerance and muscle weakness due to impaired glycogen breakdown. PHKB another homologous phosphorylase kinase subunit can connect to similar energy metabolism disruptions showing a clear association with the disorder pathway alongside PHKA1.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Sanger Sequencing - Human PHKA1 knockout HEK-293T cell lysate (ab258111)
Homozygous: 2 bp deletion in exon14
Western blot - Human PHKA1 knockout HEK-293T cell lysate (ab258111)
Lanes 1 - 2: Western blot - Anti-PHKA1 antibody [EPR12118] - BSA and Azide free (Anti-PHKA1 antibody [EPR12118] - BSA and Azide free ab249913) at 1/1000 dilution
Lanes 1 - 2: Western blot - Anti-PHKA1 antibody [EPR12118] (Anti-PHKA1 antibody [EPR12118] ab176338) at 1/1000 dilution
Lane 1: Wild-type HEK-293T cell lysate at 20 µg
Lane 2: PHKA1 knockout HEK-293T cell lysate at 20 µg
Lane 2: Western blot - Human PHKA1 knockout HEK-293T cell line (Human PHKA1 knockout HEK-293T cell line ab267337)
Lane 2: Western blot - Human PHKA1 knockout HEK-293T cell lysate (ab258111)
SecondaryAll lanes: Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Performed under reducing conditions.
Observed band size: 130 kDa
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com